IOL Chemicals and Pharmaceuticals announced Q4FY23 & FY23 result: Q4FY23: Total income for Q4FY23 stood at Rs 596 crore as against Rs 530 crore in Q3FY23 EBITDA for Q4FY23 at Rs 104 crore as compared to Rs 50 crore in Q3FY23 Net profit for Q4FY23 at Rs 65 crore as compared to Rs 24 crore in Q3FY23 FY23: Total income for FY23 stood at Rs 2,243 crore as compared to Rs 2,216 crore in FY22 EBITDA for FY23 at Rs 252 crore as compared to Rs 288 crore in FY22 Net profit for FY23 at Rs 140 crore as compared to Rs 166 crore in FY22 Commenting on the performance, Vikas Gupta, Joint Managing Director said, “The last quarter of the financial year has come out strong for us as we stabilized our operations in pharma and specialty chemicals segments with a focus on cost rationalisation and margin improvement. With significant operational, technical and commercial efficiencies, improved market combination and expecting sustainable demand as an alternative to China, we believe we are on a good upward trajectory." Result PDF
IOL Chemicals and Pharmaceuticals announced Q3FY23 results: Q3FY23: Total income stood at Rs 530 crore against Rs 546 crore QoQ and Rs 564 crore YoY EBITDA at Rs 50 crore as compared to Rs 37 crore QoQ and Rs 68 crore YoY Net profit of the company at Rs 24.15 crore against Rs 15.67 crore QoQ and Rs 40.07 crore YoY Paracetamol capacity expansion by 1,800 MTPA completed Company focusing on frugal manufacturing practices to reduce raw material costs and expand margins Commenting on the quarterly performance, Dr Sanjay Chaturvedi, Executive Director & CEO said, “The quarterly performance reflects our commitment to control our costs and improve our margin trajectory. For the third quarter, EBITDA and net profit margins – both improved sequentially. Apart from cost rationalisation, we have completed our capacity enhancement of Paracetamol by 1,800 MTPA to take total capacity to 3,600 MTPA with backward integration of Para Amino Phenol (PAP) and we expect this capacity enhancement to boost volume growth from next quarter onwards.” Result PDF
Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.
IOL Chemicals and Pharmaceuticals announced Q2FY23 results: Total income stood at Rs 546 crore against Rs 570 crore QoQ and Rs 548 crore YoY EBITDA at Rs 37 crore as compared to Rs 61 crore QoQ and Rs 54 crore YoY Net profit of the Company at Rs 15.6 crore against Rs 34.9 crore QoQ and Rs 30.8 crore YoY Sanjay Chaturvedi, Executive Director & CEO, said, “The global economy is going through a roller-coaster ride as central banks battle inflation through rate hikes. Apart from inflation, global trade is also impacted by the uncertain business environment following Russia’s invasion of Ukraine and frequent lockdowns in China, thereby leading to supply chain disruptions. For the Indian API manufacturers and speciality chemicals players, the major challenge comes from volatile input costs with raw material and energy prices both impacting profitability. However, we expect the headwinds to subside going into the second half of this financial year and strongly believe that the worst is behind us in terms of challenges. IOL Chemicals has improved the operational efficiency over the last few quarters and we believe this would give us an edge in terms of expanding our margins next quarter onwards.” Result PDF
Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
IOL Chemicals and Pharmaceuticals announced Q1FY23 Result Net profit of the Company at Rs 34.9 Cr against Rs. 27.8 Cr QoQ and Rs. 67 Cr YoY Total Income stood at Rs 570.2 Cr against Rs. 579.4 Cr QoQ and Rs 524.2 Cr YoY EBITDA at Rs. 61.2 Cr as compared to Rs. 50.1 Cr QoQ and Rs 115.9 Cr YoY Commenting on the performance of the Company during the quarter, Dr Sanjay Chaturvedi, Executive Director & CEO said, “Over the next few years, our focus will be on diversifying into other speciality chemical products and increase the share of non-Ibuprofen business. The investment planned in setting up a new plant will aid the Company in strengthening its position in both, Domestic and Export markets, thereby helping in improving our market share. Over the course of next few quarters, the Company’s plan to explore new geographies and de-risk the business with continuous backward integration model will play out leading to improvement in revenue as well as profitability.” “Various business challenges of softening demand, rising inputs costs and volatility in chemical prices are slowly getting normalised as can be seen from recovery in EBITDA margins. However, we believe that the challenges are a temporary phenomenon. The robust global demand on specialty chemicals fronts owing to shift in market share from China would benefit the sector over next few years”, Dr Chaturvedi said. Result PDF
Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
IOL Chemicals and Pharmaceuticals declares Q3FY22 result: IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of Pharmaceutical (APIs) and Specialty Chemicals today posted its audited financial results for the quarter and nine months ending 31 st December 2021. The Company on QoQ basis recorded 3% growth in total income, the EBITDA has been increased by about 26% on QoQ basis. Dr Sanjay Chaturvedi, Chief Executive Officer said “the continuous volatility in the Chemicals pricing and lower volume of API products has impacted our margins on YoY basis while Q3 results show significant improvement from Q2. During Q3, the Company filed 4 DMFs with USFDA and 6 products have got GMP certificate from MOH Russia. Additionally, the company got approval from KFDA (Korean FDA) for 2 products. All these regulatory approvals will enable the Company for increased market penetration and add value to the business. With shaping up of improved operational efficiencies, cost cutting measures and investment in human capital, we are confident that the Company is on the way to sustainable growth.” Result PDF